B
BioAge Labs
BIOAGE discovers and develops drugs to treat aging and associated diseases
About BioAge Labs
BioAge Labs is a clinical-stage biotechnology company that operates in the healthcare sector, specifically focusing on the development of therapies for age-related diseases. The company's primary mission is to map human aging and use this information to create a range of treatments that not only combat diseases but also extend a healthy lifespan.
Their business model revolves around their unique human-first discovery platform. This platform translates insights from human aging profiles into a diverse portfolio of drugs. These drugs are then used to create medicines that treat or prevent diseases of aging in entirely new ways. Essentially, BioAge Labs is redefining the concept of healthy aging with their longevity-focused therapeutics.
The company's target market includes individuals suffering from age-related diseases, a group that represents a significant unmet medical need. By focusing on this market, BioAge Labs is positioning itself at the forefront of a key moment of opportunity for longevity medicine.
BioAge Labs makes money by developing and selling their unique, longevity-focused therapeutics. As they progress through the clinical stages and their drugs receive approval, they will be able to sell these treatments to healthcare providers and patients.
In summary, BioAge Labs is a pioneering biotechnology company that is using innovative technology and scientific progress to develop treatments for age-related diseases and extend healthy human lifespan.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- Emeryville, United States
- Employees
- 99
- Open positions
- None listed
- Dealroom signal
- 80.7/100
- Industry
- Health
- Sub-industry
- BioTechnology, Health Platform
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Weight Management, Core AI, Tech for Biotech and Pharma, Rumoured $1B, Biotech and Pharma
- Technology
- Artificial Intelligence, Machine Learning
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES DOther financing | Feb 2024 | $170M | $680M | Andreessen Horowitz · Lilly Ventures · Amgen Ventures · Longitude Capital | ↗ |
| SERIES COther financing | Dec 2020 | $90M | $360M | Redpoint · Elad Gil · Caffeinated Capital · Phi-X Capital | — |
Growth signals
Latest recorded traffic for BioAge Labs is 12K monthly website visits, up 30.4% over the last three months. BioAge Labs's team grew 2.1% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Series B and later17 investors entered at this stage
Khosla Ventures
Gil Capital
Redpoint
Phi-X Capital
AARP Community
Kaiser Permanente
Sofinnova Investments
Lilly Ventures
Amgen Ventures
Longitude Capital
Cormorant Asset Management
RTW Investments
RA Capital Management
Pivotal BioVenture Partners
Osage University Partners
OrbiMed
SV Health Investors
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about BioAge Labs on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See BioAge Labs’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.